Literature DB >> 16894031

mTOR-independent translational control of the extrinsic cell death pathway by RalA.

Amith Panner1, Jean L Nakamura, Andrew T Parsa, Pablo Rodriguez-Viciana, Mitchel S Berger, David Stokoe, Russell O Pieper.   

Abstract

Oncogenic potential is associated with translational regulation, and the prevailing view is that oncogenes use mTOR-dependent pathways to up-regulate the synthesis of proteins critical for transformation. In this study, we show that RalA, a key mediator of Ras transformation, is also linked to the translational machinery. At least part of this linkage, however, is independent of mTOR and acts through RalBP1 to suppress cdc42-mediated activation of S6 kinase and the translation of the antiapoptotic protein FLIP(S). This action, rather than contributing to transformation, opens a latent tumor-suppressive mechanism that can be activated by tumor necrosis factor-related apoptosis-inducing ligand. These results show that the translational machinery is linked to tumor suppression as well as cell-proliferative pathways and that the reestablishment of cell death pathways by activation of the Ral oncogenic program provides a means for selective therapeutic targeting of Ral-driven malignancies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16894031      PMCID: PMC1636864          DOI: 10.1128/MCB.00126-06

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  51 in total

1.  RalA but not RalB enhances polarized delivery of membrane proteins to the basolateral surface of epithelial cells.

Authors:  Michail Shipitsin; Larry A Feig
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

2.  The 70 kDa S6 kinase complexes with and is activated by the Rho family G proteins Cdc42 and Rac1.

Authors:  M M Chou; J Blenis
Journal:  Cell       Date:  1996-05-17       Impact factor: 41.582

3.  A novel family of Ras-binding domains.

Authors:  C P Ponting; D R Benjamin
Journal:  Trends Biochem Sci       Date:  1996-11       Impact factor: 13.807

4.  Atypical protein kinases Clambda and -zeta associate with the GTP-binding protein Cdc42 and mediate stress fiber loss.

Authors:  M P Coghlan; M M Chou; C L Carpenter
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

5.  Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development.

Authors:  Takeshi Ueda; Rie Watanabe-Fukunaga; Hidehiro Fukuyama; Shigekazu Nagata; Rikiro Fukunaga
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

6.  Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway.

Authors:  Yan Wang; Ingo H Engels; Deborah A Knee; Marc Nasoff; Quinn L Deveraux; Kim C Quon
Journal:  Cancer Cell       Date:  2004-05       Impact factor: 31.743

7.  Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis.

Authors:  Alexandre Nesterov; Malti Nikrad; Thomas Johnson; Andrew S Kraft
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

8.  Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity.

Authors:  M Stacey Ricci; Zhaoyu Jin; Michael Dews; Duonan Yu; Andrei Thomas-Tikhonenko; David T Dicker; Wafik S El-Deiry
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

9.  Bridging Ral GTPase to Rho pathways. RLIP76, a Ral effector with CDC42/Rac GTPase-activating protein activity.

Authors:  V Jullien-Flores; O Dorseuil; F Romero; F Letourneur; S Saragosti; R Berger; A Tavitian; G Gacon; J H Camonis
Journal:  J Biol Chem       Date:  1995-09-22       Impact factor: 5.157

10.  Identification and characterization of Ral-binding protein 1, a potential downstream target of Ral GTPases.

Authors:  S B Cantor; T Urano; L A Feig
Journal:  Mol Cell Biol       Date:  1995-08       Impact factor: 4.272

View more
  15 in total

1.  Novel role of c-jun N-terminal kinase in regulating the initiation of cap-dependent translation.

Authors:  Manish R Patel; Ahad A Sadiq; Joe Jay-Dixon; Tanawat Jirakulaporn; Blake A Jacobson; Faris Farassati; Peter B Bitterman; Robert A Kratzke
Journal:  Int J Oncol       Date:  2011-11-04       Impact factor: 5.650

2.  RalA function in dermal fibroblasts is required for the progression of squamous cell carcinoma of the skin.

Authors:  Adam G Sowalsky; Addy Alt-Holland; Yulia Shamis; Jonathan A Garlick; Larry A Feig
Journal:  Cancer Res       Date:  2010-12-15       Impact factor: 12.701

3.  Overexpression of RalBP1 in colorectal cancer is an independent predictor of poor survival and early tumor relapse.

Authors:  Nathan M Mollberg; Gunnar Steinert; Maximillian Aigner; Alexander Hamm; Fang-Ju Lin; Heike Elbers; Christoph Reissfelder; Jürgen Weitz; Markus W Buchler; Moritz Koch
Journal:  Cancer Biol Ther       Date:  2012-06-01       Impact factor: 4.742

4.  KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels.

Authors:  David Llobet; Nuria Eritja; Monica Domingo; Laura Bergada; Cristina Mirantes; Maria Santacana; Judit Pallares; Anna Macià; Andree Yeramian; Mario Encinas; Gema Moreno-Bueno; Jose Palacios; Robert E Lewis; Xavier Matias-Guiu; Xavi Dolcet
Journal:  Am J Pathol       Date:  2011-04       Impact factor: 4.307

Review 5.  Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy.

Authors:  Ahmad R Safa; Travis W Day; Ching-Huang Wu
Journal:  Curr Cancer Drug Targets       Date:  2008-02       Impact factor: 3.428

6.  RalA suppresses early stages of Ras-induced squamous cell carcinoma progression.

Authors:  A G Sowalsky; A Alt-Holland; Y Shamis; J A Garlick; L A Feig
Journal:  Oncogene       Date:  2009-10-05       Impact factor: 9.867

Review 7.  c-FLIP, a master anti-apoptotic regulator.

Authors:  A R Safa
Journal:  Exp Oncol       Date:  2012-10

8.  Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer.

Authors:  Sharad S Singhal; Archana Sehrawat; Mukesh Sahu; Preeti Singhal; Rit Vatsyayan; Poorna Chandra Rao Lelsani; Sushma Yadav; Sanjay Awasthi
Journal:  Int J Cancer       Date:  2010-03-15       Impact factor: 7.396

9.  A novel PTEN-dependent link to ubiquitination controls FLIPS stability and TRAIL sensitivity in glioblastoma multiforme.

Authors:  Amith Panner; Courtney A Crane; Changjiang Weng; Alberto Feletti; Andrew T Parsa; Russell O Pieper
Journal:  Cancer Res       Date:  2009-10-06       Impact factor: 12.701

10.  RLIP76: a target for kidney cancer therapy.

Authors:  Sharad S Singhal; Jyotsana Singhal; Sushma Yadav; Mukesh Sahu; Yogesh C Awasthi; Sanjay Awasthi
Journal:  Cancer Res       Date:  2009-05-05       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.